Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 349 to 142 of 142 entries
Sorted by: Best Match Show Resources per page
N,N'-Dicyanoquinone diimide-derived donor-acceptor chromophores: conformational analysis and optoelectronic properties.

Organic letters

Chiu M, Jaun B, Beels MT, Biaggio I, Gisselbrecht JP, Boudon C, Schweizer WB, Kivala M, Diederich F.
PMID: 22124331
Org Lett. 2012 Jan 06;14(1):54-7. doi: 10.1021/ol202815q. Epub 2011 Nov 29.

A formal [2 + 2] cycloaddition-cycloreversion (CA-CR) between N,N'-dicyanoquinone diimides (DCNQIs) and electron-rich alkynes was explored, providing a new class of π-conjugated donor-acceptor chromophores. These DCNQI adducts exist in the solid state as single diastereoisomers, but as two interconverting...

Controlling photoionization using attosecond time-slit interferences.

Proceedings of the National Academy of Sciences of the United States of America

Cheng YC, Mikaelsson S, Nandi S, Rämisch L, Guo C, Carlström S, Harth A, Vogelsang J, Miranda M, Arnold CL, L'Huillier A, Gisselbrecht M.
PMID: 32354996
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10727-10732. doi: 10.1073/pnas.1921138117. Epub 2020 Apr 30.

When small quantum systems, atoms or molecules, absorb a high-energy photon, electrons are emitted with a well-defined energy and a highly symmetric angular distribution, ruled by energy quantization and parity conservation. These rules are based on approximations and symmetries...

Efficient Transfection of Large Plasmids Encoding HIV-1 into Human Cells-A High Potential Transfection System Based on a Peptide Mimicking Cationic Lipid.

Pharmaceutics

Janich C, Ivanusic D, Giselbrecht J, Janich E, Pinnapireddy SR, Hause G, Bakowsky U, Langner A, Wölk C.
PMID: 32854383
Pharmaceutics. 2020 Aug 25;12(9). doi: 10.3390/pharmaceutics12090805.

One major disadvantage of nucleic acid delivery systems is the low transfection or transduction efficiency of large-sized plasmids into cells. In this communication, we demonstrate the efficient transfection of a 15.5 kb green fluorescent protein (GFP)-fused HIV-1 molecular clone...

Improving Second-Line Therapy in Aggressive Non-Hodgkin's Lymphoma.

Seminars in oncology

Gisselbrecht C, Mounier N.
PMID: 28140103
Semin Oncol. 2004 Feb;31:12-16. doi: 10.1053/j.seminoncol.2003.12.004.

The prognosis is poor for patients relapsing following treatment with standard chemotherapy for aggressive non-Hodgkin's lymphoma. High-dose therapy and autologous stem cell transplantation is a potential curative approach for these patients. The primary aim of second-line therapy is the...

VEGF.

Oncotarget

Broséus J, Mourah S, Ramstein G, Bernard S, Mounier N, Cuccuini W, Gaulard P, Gisselbrecht C, Brière J, Houlgatte R, Thieblemont C.
PMID: 29207605
Oncotarget. 2017 Jul 19;8(53):90808-90824. doi: 10.18632/oncotarget.19385. eCollection 2017 Oct 31.

Tumor microenvironment including endothelial and immune cells plays a crucial role in tumor progression and has been shown to dramatically influence cancer survival. In this study, we investigated the clinical relevance of the gene expression of key mediators of...

Rituximab: Enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma.

Seminars in oncology

Gisselbrecht C, Mounier N.
PMID: 28140218
Semin Oncol. 2003 Feb;30(1):28-33. doi: 10.1053/sonc.2003.50022.

High-dose chemotherapy and autologous stem cell transplantation (ASCT) is a potentially curative therapy for younger patients with relapsed aggressive non-Hodgkin's lymphoma, and is under investigation as first-line treatment and as therapy for indolent and mantle cell non-Hodgkin's lymphoma. However,...

EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.

The oncologist

Delgado J, Zienowicz M, van Hennik PB, Moreau A, Gisselbrecht C, Enzmann H, Pignatti F.
PMID: 34213061
Oncologist. 2021 Nov;26(11):983-987. doi: 10.1002/onco.13892. Epub 2021 Jul 19.

Isatuximab is a monoclonal antibody that binds to the human CD38 antigen. On May 30, 2020, a marketing authorization valid through the European Union (EU) was issued for isatuximab in combination with pomalidomide and dexamethasone (IsaPd) for the treatment...

Prevalence and prognostic impact of cachexia among older patients with cancer: a nationwide cross-sectional survey (NutriAgeCancer).

Journal of cachexia, sarcopenia and muscle

Poisson J, Martinez-Tapia C, Heitz D, Geiss R, Albrand G, Falandry C, Gisselbrecht M, Couderc AL, Boulahssass R, Liuu E, Boudou-Rouquette P, Chah Wakilian A, Gaxatte C, Pamoukdjian F, de Decker L, Antoine V, Cattenoz C, Solem-Laviec H, Guillem O, Medjenah H, Natella PA, Canouï-Poitrine F, Laurent M, Paillaud E.
PMID: 34519440
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1477-1488. doi: 10.1002/jcsm.12776. Epub 2021 Sep 14.

BACKGROUND: Nutritional impairment is common in cancer patients and is associated with poor outcomes. Only few studies focused on cachexia. We assessed the prevalence of cachexia in older cancer patients, identified associated risk factors, and evaluated its impact on...

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease.

HemaSphere

Delgado J, Voltz C, Stain M, Lapveteläinen T, Urach S, Lähteenvuo J, Penttilä K, Gisselbrecht C, Enzmann H, Pignatti F.
PMID: 34235401
Hemasphere. 2021 Jun 28;5(7):e604. doi: 10.1097/HS9.0000000000000604. eCollection 2021 Jul.

Crizanlizumab is a monoclonal antibody that binds to P-selectin. On October 28, 2020, a conditional marketing authorization valid through the European Union (EU) was issued for crizanlizumab for the prevention of recurrent vaso-occlusive crises (VOCs) in patients with sickle...

Prevalence and prognostic impact of cachexia among older patients with cancer: a nationwide cross-sectional survey (NutriAgeCancer).

Journal of cachexia, sarcopenia and muscle

Poisson J, Martinez-Tapia C, Heitz D, Geiss R, Albrand G, Falandry C, Gisselbrecht M, Couderc AL, Boulahssass R, Liuu E, Boudou-Rouquette P, Chah Wakilian A, Gaxatte C, Pamoukdjian F, de Decker L, Antoine V, Cattenoz C, Solem-Laviec H, Guillem O, Medjenah H, Natella PA, Canouï-Poitrine F, Laurent M, Paillaud E.
PMID: 34519440
J Cachexia Sarcopenia Muscle. 2021 Sep 14; doi: 10.1002/jcsm.12776. Epub 2021 Sep 14.

BACKGROUND: Nutritional impairment is common in cancer patients and is associated with poor outcomes. Only few studies focused on cachexia. We assessed the prevalence of cachexia in older cancer patients, identified associated risk factors, and evaluated its impact on...

Showing 349 to 142 of 142 entries